JP2021526816A5 - - Google Patents

Info

Publication number
JP2021526816A5
JP2021526816A5 JP2020568407A JP2020568407A JP2021526816A5 JP 2021526816 A5 JP2021526816 A5 JP 2021526816A5 JP 2020568407 A JP2020568407 A JP 2020568407A JP 2020568407 A JP2020568407 A JP 2020568407A JP 2021526816 A5 JP2021526816 A5 JP 2021526816A5
Authority
JP
Japan
Prior art keywords
human
antibody
antigen
present
binding
Prior art date
Application number
JP2020568407A
Other languages
English (en)
Japanese (ja)
Other versions
JP7133043B2 (ja
JP2021526816A (ja
JPWO2019234220A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/064942 external-priority patent/WO2019234220A1/en
Publication of JP2021526816A publication Critical patent/JP2021526816A/ja
Publication of JPWO2019234220A5 publication Critical patent/JPWO2019234220A5/ja
Publication of JP2021526816A5 publication Critical patent/JP2021526816A5/ja
Priority to JP2022134954A priority Critical patent/JP2022180379A/ja
Application granted granted Critical
Publication of JP7133043B2 publication Critical patent/JP7133043B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020568407A 2018-06-09 2019-06-07 Ｄｌｌ３－ｃｄ３二重特異性抗体 Active JP7133043B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022134954A JP2022180379A (ja) 2018-06-09 2022-08-26 Ｄｌｌ３－ｃｄ３二重特異性抗体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP18176888 2018-06-09
EP18176888.8 2018-06-09
EP18176889 2018-06-09
EP18176889.6 2018-06-09
EP19159321.9 2019-02-26
EP19159321 2019-02-26
PCT/EP2019/064942 WO2019234220A1 (en) 2018-06-09 2019-06-07 Dll3-cd3 bispecific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022134954A Division JP2022180379A (ja) 2018-06-09 2022-08-26 Ｄｌｌ３－ｃｄ３二重特異性抗体

Publications (4)

Publication Number Publication Date
JP2021526816A JP2021526816A (ja) 2021-10-11
JPWO2019234220A5 JPWO2019234220A5 (https=) 2022-06-09
JP2021526816A5 true JP2021526816A5 (https=) 2022-06-09
JP7133043B2 JP7133043B2 (ja) 2022-09-07

Family

ID=66752128

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020568407A Active JP7133043B2 (ja) 2018-06-09 2019-06-07 Ｄｌｌ３－ｃｄ３二重特異性抗体
JP2022134954A Pending JP2022180379A (ja) 2018-06-09 2022-08-26 Ｄｌｌ３－ｃｄ３二重特異性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022134954A Pending JP2022180379A (ja) 2018-06-09 2022-08-26 Ｄｌｌ３－ｃｄ３二重特異性抗体

Country Status (32)

Country Link
US (3) US11332541B2 (https=)
EP (2) EP4566621A3 (https=)
JP (2) JP7133043B2 (https=)
KR (1) KR20210018311A (https=)
CN (7) CN119499365A (https=)
AU (1) AU2019280900B2 (https=)
BR (1) BR112020022898A2 (https=)
CA (1) CA3099956A1 (https=)
CL (1) CL2020003105A1 (https=)
CO (1) CO2020015172A2 (https=)
CR (1) CR20200601A (https=)
DK (1) DK3802598T3 (https=)
EC (1) ECSP20084864A (https=)
ES (1) ES3021463T3 (https=)
FI (1) FI3802598T3 (https=)
HR (1) HRP20250443T1 (https=)
HU (1) HUE071620T2 (https=)
IL (1) IL279235A (https=)
JO (1) JOP20200313A1 (https=)
LT (1) LT3802598T (https=)
MA (1) MA52742B1 (https=)
MX (1) MX2020013348A (https=)
MY (1) MY199655A (https=)
PE (1) PE20210321A1 (https=)
PH (1) PH12020552080A1 (https=)
PL (1) PL3802598T3 (https=)
RS (1) RS66693B1 (https=)
SA (1) SA520420748B1 (https=)
SG (1) SG11202011134XA (https=)
SI (1) SI3802598T1 (https=)
TW (1) TWI848953B (https=)
WO (1) WO2019234220A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
CA3097193A1 (en) 2018-05-08 2019-11-14 Phanes Therapeutics, Inc. Anti-dll3 antibodies and uses thereof
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
BR112021005472A2 (pt) 2018-09-28 2021-06-15 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno compreendendo uma região variável do anticorpo alterada
US12534516B2 (en) * 2018-10-22 2026-01-27 International Aids Vaccine Initiative Anti-HIV antibodies
TWI878355B (zh) * 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
EP4097135A4 (en) * 2020-01-31 2024-07-03 Gensun Biopharma Inc. Bispecific t cell engagers
TWI909146B (zh) * 2020-03-31 2025-12-21 日商中外製藥股份有限公司 Dll3靶向之多特異性抗原結合分子及其用途
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
PH12022500025A1 (en) * 2020-05-20 2024-03-25 Univ Columbia Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
CN111551733A (zh) * 2020-05-29 2020-08-18 武汉大学 定量检测免疫细胞来源细胞外囊泡pd-1含量的方法、elisa试剂盒及使用方法
EP4214233A1 (en) 2020-09-16 2023-07-26 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
AU2021372988A1 (en) * 2020-11-06 2023-06-22 Board Of Regents, The University Of Texas System Methods and systems for classification and treatment of small cell lung cancer
CA3204628A1 (en) * 2021-01-13 2022-07-21 John T. POIRIER Antibody-pyrrolobenzodiazepine derivative conjugate
TW202245844A (zh) * 2021-01-13 2022-12-01 紀念斯隆凱特琳癌症中心 抗dll3抗體-藥物結合物
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
CN117529337A (zh) * 2021-05-08 2024-02-06 上海齐鲁制药研究中心有限公司 针对dll3的结合分子及其应用
US20240317856A1 (en) * 2021-05-10 2024-09-26 Amgen Inc. Dosing regimen for combination therapy targeting dll3 and pd-1
WO2023031409A1 (en) 2021-09-02 2023-03-09 Boehringer Ingelheim International Gmbh Method of determining a future color value or corresponding property and arrangement therefor
TW202346346A (zh) * 2021-12-23 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｄｌｌ３抗體、其抗體－藥物偶聯物及其醫藥用途
AU2023217790A1 (en) * 2022-02-10 2024-08-22 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Bispecific antigen-binding molecule and use thereof
JP2025508786A (ja) 2022-02-23 2025-04-10 アムジェン インコーポレイテッド Ｄｌｌ３を標的とする癌治療
EP4545564A4 (en) * 2022-06-23 2026-01-14 Jiangsu Hengrui Pharmaceuticals Co Ltd Antigen-binding molecule specifically binding to DLL3 and CD3, and its pharmaceutical use
TW202432545A (zh) 2022-10-26 2024-08-16 德商百靈佳殷格翰國際股份有限公司 可活化sting之雜環化合物
TW202432114A (zh) 2022-10-26 2024-08-16 德商百靈佳殷格翰國際股份有限公司 可活化sting之雜環化合物
CA3267008A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING
US20240166705A1 (en) 2022-11-07 2024-05-23 Xencor, Inc. Il18-fc fusion proteins
EP4630458A2 (en) * 2022-12-08 2025-10-15 Amgen Inc. Methods for treating dll3-expressing cancer
WO2024159174A1 (en) * 2023-01-27 2024-08-02 The United States Goverment As Represented By The Department Of Veterans Affairs Compositions for treating tauopathies and methods of use thereof
IL322887A (en) 2023-02-27 2025-10-01 Suzhou Suncadia Biopharmaceuticals Co Ltd Anti-DLL3 antibody, antibody-drug conjugate and pharmaceutical use thereof
TW202509075A (zh) 2023-05-19 2025-03-01 德商百靈佳殷格翰國際股份有限公司 T細胞銜接蛋白治療癌症之用途
WO2025131024A1 (zh) * 2023-12-22 2025-06-26 江苏恒瑞医药股份有限公司 一种包含特异性结合dll3和cd3的双特异性抗体的药物组合物
WO2025146127A1 (zh) * 2024-01-05 2025-07-10 海南先声再明医药股份有限公司 针对dll3和cd3的双特异性抗体及其应用
WO2025184731A1 (en) * 2024-03-04 2025-09-12 Zymeworks Bc Inc. Trispecific antibody constructs targeting dll3 and methods of use thereof
TW202602488A (zh) 2024-03-11 2026-01-16 美商安進公司 治療ｄｌｌ３陽性癌症受試者中腦轉移之方法
TW202602940A (zh) 2024-04-09 2026-01-16 美商安進公司 激動性抗ｉｌ－２ｒｂｇ重鏈抗體
WO2026060304A1 (en) 2024-09-13 2026-03-19 Amgen Inc. Subcutaneous administration of anti-dll3 agent for treatment of cancer
WO2026075950A1 (en) 2024-10-01 2026-04-09 Amgen Inc. Dosing regimen for anti-dll3 agent

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731A (en) 1848-08-22 Elisha k
US168A (en) 1837-04-17 Improvement in fire-arms
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
CA2097060A1 (en) 1990-12-04 1992-06-05 Peter J. Curtis Bifunctional antibodies and method of preparing same
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
ATE218143T1 (de) 1996-09-03 2002-06-15 Gsf Forschungszentrum Umwelt Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
EP1409240B1 (en) 2001-07-20 2012-05-09 Life Technologies Corporation Luminescent nanoparticles and methods for their preparation
KR20060041205A (ko) 2003-07-01 2006-05-11 이뮤노메딕스, 인코오포레이티드 양특이성 항체들의 다가 담체들
NZ563202A (en) 2005-07-15 2011-02-25 Nissan Chemical Ind Ltd Thiophene compounds and thrombopoietin receptor activators
AU2006301492B2 (en) * 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
EP2860192B1 (en) 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
US20070141066A1 (en) 2005-12-16 2007-06-21 Genentech, Inc. Method for Diagnosing, Prognosing and Treating Glioma
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
PE20110220A1 (es) 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
TW201100543A (en) * 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
JP5787891B2 (ja) 2009-09-01 2015-09-30 ジェネンテック， インコーポレイテッド 改変されたプロテインａ溶離による向上したタンパク質精製
CA2777527C (en) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
EP3907242A1 (en) 2010-01-29 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
US8916162B2 (en) 2010-02-20 2014-12-23 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CN114805583A (zh) 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体
EP3029066B1 (en) 2010-07-29 2019-02-20 Xencor, Inc. Antibodies with modified isoelectric points
WO2012106578A1 (en) 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
IN2013MN01438A (https=) 2011-03-17 2015-06-12 Univ Ramot
JP6177231B2 (ja) 2011-04-20 2017-08-09 ゲンマブ エー／エス Ｈｅｒ２に対する二重特異性抗体
CA2832389A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
DK2723769T4 (da) 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
SG2014010482A (en) 2011-08-17 2014-04-28 Glaxo Group Ltd Modified proteins and peptides
CN107266577B (zh) 2011-10-11 2022-09-13 弗·哈夫曼-拉罗切有限公司 双特异性抗体的改进的组装
US10344050B2 (en) 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
LT2794905T (lt) * 2011-12-20 2020-07-10 Medimmune, Llc Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
US20140072581A1 (en) * 2012-07-23 2014-03-13 Zymeworks Inc. Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
US20150016666A1 (en) 2012-11-02 2015-01-15 Google Inc. Method and Apparatus for Determining Geolocation of Image Contents
EP3878964A1 (en) 2012-11-27 2021-09-15 Ajou University Industry-Academic Cooperation Foundation Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
AR095774A1 (es) 2013-04-05 2015-11-11 Genentech Inc Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos
RU2687043C2 (ru) 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
TWI651300B (zh) 2013-05-17 2019-02-21 健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
UA129760C2 (uk) * 2013-12-17 2025-07-30 Дженентек, Інк. Анти-cd3 антитіло та спосіб його застосування
WO2015118057A1 (en) 2014-02-06 2015-08-13 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CA2943707A1 (en) 2014-05-06 2015-11-12 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells
JP7020909B2 (ja) * 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
AU2015295242B2 (en) * 2014-07-31 2020-10-22 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
UA123624C2 (uk) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
BR112017006591A2 (pt) 2014-11-06 2018-01-16 Hoffmann La Roche polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
WO2017004149A1 (en) * 2015-06-30 2017-01-05 Boehringer Ingelheim International Gmbh Multi-specific binding proteins
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
AU2016307955A1 (en) * 2015-08-17 2018-03-08 Macrogenics, Inc. Bispecific monovalent diabodies that are capable of binding B7-H3 and CD3, and uses thereof
AU2017266298B2 (en) 2016-05-18 2024-01-04 Boehringer Ingelheim International Gmbh Anti PD-1 and anti-LAG3 antibodies for cancer treatment
US11667713B2 (en) * 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
BR112020020604A2 (pt) * 2018-04-11 2021-01-12 Inhibrx, Inc. Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
KR102839606B1 (ko) 2018-12-31 2025-07-29 삼성디스플레이 주식회사 색변환 기판 및 표시 장치
BR112023019458A2 (pt) * 2021-03-24 2023-12-05 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de cd3 e usos dos mesmos

Similar Documents

Publication Publication Date Title
JP2021526816A5 (https=)
JP7453206B2 (ja) 改良された血清アルブミン結合剤
US20240124584A1 (en) Igm fc and j-chain mutations that affect igm serum half-life
JP7195142B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
CN113943366B (zh) 新型抗体框架
JPWO2019234220A5 (https=)
JP2912618B2 (ja) 組換えｄｎａ生産物及び製造法
AU2015322141B2 (en) High affinity and aggregatively stable antibodies on the basis of variable domains Vl and a derivative VHH
JP2020506898A5 (https=)
JP2022512043A (ja) 合理的に設計された新規なタンパク質組成物
JP2015504896A5 (https=)
JP2006506955A5 (https=)
CA3118640A1 (en) Single domain antibodies that bind human serum albumin
CN111201246A (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
EA026375B1 (ru) Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р
TWI906795B (zh) 特異性結合Ｃｌａｕｄｉｎ １８.２的抗體及其製法和應用
CN120077069A (zh) 趋化因子受体8（ccr8）抗体
WO2025152667A1 (zh) 抗人cd117单克隆抗体及其应用
TWI867354B (zh) 新穎Nav1.7單株抗體
CN116333127B (zh) 靶向人lilrb2的纳米抗体及其应用
TWI615408B (zh) 人源化之單株抗體及其用途
JP5587792B2 (ja) 精製タグ又は不活性可変ドメインを具えるタンパク性結合分子
JP2025508603A (ja) ネコ抗体ライブラリー
RU2025110616A (ru) CD163 Связывающий белок
TW202417506A (zh) 標靶egfr之雙抗原決定四價抗體